Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C TIL051

Drug Profile

C TIL051

Alternative Names: Autologous tumour infiltrating lymphocytes - AbelZeta Pharma; C-TIL-051; TIL-1

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group
  • Developer AbelZeta Pharma
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
  • 27 Sep 2023 Cellular Biomedicine Group and Nektar Therapeutics enter R&D agreement to evaluate C TIL051 in combination with NKTR 255 in a phase I trial for Non-small cell lung cancer
  • 27 Sep 2023 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Refractory metastatic disease, Recurrent) in USA (Parenteral) (NCT05676749)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top